International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018

Re- Envisioning Transformative Approaches to Ameloblastoma: Bridging Innovation and Patient Care

Richa Wadhawan[1], Prerna Kumari [2], Ananya Mondal[3], Harsh Kumar Srivastava[4], Upika Jain [5], Harshika Sengar [6]

1. Professor, Oral Medicine, Diagnosis & Radiology, PDM Dental College & Research Institute, Bahadurgarh, Haryana

2. Post graduate, Oral and Maxillofacial Surgery, Shree Bankey Bihari Dental College & Research Centre, Ghaziabad, Uttar Pradesh

3. Post graduate, Oral and Maxillofacial Surgery, Shree Bankey Bihari Dental College & Research Centre, Ghaziabad, Uttar Pradesh

4. Post graduate, Oral and Maxillofacial Surgery, Shree Bankey Bihari Dental College & Research Centre, Ghaziabad, Uttar Pradesh

5. Post graduate, Oral and Maxillofacial Surgery, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, Uttar Pradesh

6. Dental surgeon, Institute of Dental Education & Advance Studies, Gwalior, Madhya Pradesh

Submitted: 01-11-2024 Accepted: 10-11-2024

ABSTRACT: Ameloblastoma is a rare odontogenic neoplasm primarily affecting the mandible and maxilla, characterized by diverse histologic subtypes and a high recurrence rate if inadequately managed. This benign yet locally aggressive tumor presents significant treatment challenges due to its complexity. The primary intervention remains wide local excision with appropriate margins and immediate reconstruction. Recent advancements in imaging techniques, particularly high-resolution 3D imaging, enhance diagnostic precision and facilitate effective surgical planning. Furthermore, state-of-the-art surgical methods, including minimally invasive techniques and innovative reconstructive strategies, prioritize functionality and aesthetics, ultimately improving patient quality of life. By consolidating various research findings with clinical practices, it offers a comprehensive perspective on how technology and interdisciplinary collaboration, particularly between oral and maxillofacial surgeons, oral radiologists, oral pathologists and oncologists can optimize patient outcomes, setting a new standard of care. Additionally, recent molecular profiling of these tumors may open avenues for personalized treatment options, further enhancing outcomes and transforming ameloblastoma management.

Key words: Ameloblastoma, Odontogenic tumors, Minimally invasive surgery, Imaging techniques, Recurrence rates, Reconstructive surgery

I. INTRODUCTION:

Ameloblastoma is characterized as "usually unicentric, nonfunctional, grows intermittently, anatomically benign, and clinically persistent," according to Robinson. As a true tumor composed of enamel organ-type tissue, it stands as the second most common odontogenic tumor.[1] The name itself is derived from the early English word "amel," meaning "enamel," and the Greek "blastos," meaning "germ."[2] First recognized by Cusack in 1827, it was later termed adamantinoma by Louis Charles Malassez due to its resemblance to a bone tumor. [3] The term "ameloblastoma" was introduced by Churchill and Ivey in 1934, following Falkson's detailed description in 1879.[4] Despite its benign classification, ameloblastoma is a locally aggressive tumor that can originate from enamel, dental follicles, periodontal ligaments, or the lining of odontogenic cysts.[5] It is the most prevalent odontogenic tumor, with an incidence of approximately 0.5 cases per million people, accounting for about 1% of all jaw tumors and cysts, and 10% of tumors arising in dental tissues.[6] The tumor predominantly affects the mandible—particularly the body and ascending ramus—where about 80% of cases are found: 70% in the body and 20% in the ascending branch.[7] In contrast, around 10% occur in the maxilla, mostly in the posterior region, while the maxillary sinus and floor of the nasal cavity are involved in 15% of cases (**Figure 1**).[8]

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018



Figure 1: Ameloblastoma encroaching maxillary siunus
Courtesy: Pitak-Arnnop P, Chaine A, Dhanuthai K, Bertrand JC, Bertolus C. Unicystic ameloblastoma of the maxillary sinus: pitfalls of diagnosis and management. Hippokratia. 2010; 14(3):217-20.

Areas like the mandibular premolars and maxillary canines account for 18%, with a mere 2% affecting the palate.[9] Clinically, ameloblastoma often manifests as slowly enlarging facial swellings, frequently remaining asymptomatic in the early stages.[10] This lack of symptoms can lead to delayed diagnosis, making awareness and understanding of this condition crucial for timely intervention and improved patient outcomes.[11] As they advance, they can result in significant complications, including facial asymmetry (**Figure 2**), pain, occlusal disorders, tooth displacement, root resorption, paresthesia, and erosion of bone tissue (**Figure 3**).[12]



Figure 2: External facial image showing asymmetry due to ameloblastoma
Courtesy: Hariram, Shadab Mohammad, Malkunje LR, Singh N, Das S, Mehta G. Ameloblastoma of the anterior mandible. Natl J Maxillofac Surg. 2014; 5 (1):47-50.

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018



Figure 3: Prominent intraoral characteristics of ameloblastoma
Courtesy: https://www.slideshare.net/slideshow/ameloblastoma-69909552/69909552

Rarely, ameloblastomas can transform into malignant lesions.[13] Diagnosis begins with imaging tests such as panaromic radiographs, computed tomography (CT) scans (**Figure 4**), and magnetic resonance imaging (MRIs) (**Figure 5**) to assess the tumor's extent. Many tumors are often found incidentally during routine dental examinations.[14]



Figure 4: Assessing tumor extent with CT scans
Courtesy: https://radiopaedia.org/articles/ameloblastoma

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018



Figure 5: Assessing ameloblastoma invasion: MRI insights into tumor behavior
Courtesy: Abaci M-A, Zandi A, Razmjoo H, Ghaffari S, Abtahi S-M, Jahanbani-Ardakani H, et al. Orbital invasion of ameloblastoma: A systematic review apropos of a rare entity. J Curr Glaucoma Pract. 2017; 30 (1):1-12.

Managing ameloblastoma presents significant challenges, as complete resection and functionally and aesthetically acceptable reconstruction of residual defects are critical.[15] Current treatment protocols recommend wide-margin resections with immediate reconstruction, as conservative approaches are linked to higher recurrence rates.[16] Treatment considerations for ameloblastoma should include several important factors: the patient's age, gender, symptoms, tumor type, infiltration potential, size, location, radiographic characteristics, primary surgical approaches, complications, recurrence rates, overall prognosis, and the duration of follow-up. (**Figure 6**).[17]



Figure 6: Key treatment considerations for ameloblastoma

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018

A comprehensive treatment plan based on clinical and imaging evaluations, along with complementary tests like computerized tomography and radiographs, is essential.[18] This review aims to consolidate vital information about treatment options for ameloblastomas ranging from conservative methods such as curettage and cryotherapy to more radical approaches including sclerotherapy and radiotherapy, making it more accessible for healthcare professionals and patients alike. [19] **Table 1** emphasizes comprehensive perspective the importance of collaboration between oral and maxillofacial surgeons, oral radiologists, oral pathologists and oncologists highlighting their critical roles in optimizing the management of ameloblastoma. This review consolidates the essential elements of ameloblastoma treatment, highlighting its complexity and the critical importance of a tailored, patient-centered approach. By enhancing understanding of this condition, the complexities of diagnosis and management can be better navigated, ultimately improving outcomes for those affected by ameloblastoma.[20]

Professionals	Roles and Contributions
Oral and maxillofacial Surgeons	- Perform surgical excisions and reconstructions - Utilize advanced surgical techniques for optimal outcomes - Collaborate with other specialists for comprehensive care
Oral radiologists	- Provide accurate imaging assessments for diagnosis and treatment planning - Interpret high-resolution 3D imaging to identify tumor extent and anatomical relationships - Aid in monitoring recurrence through follow-up imaging
Oral pathologists	- Provide accurate histopathological diagnosis by examining tissue samples - Classify the tumor based on its histological type (e.g., unicystic, multicystic, peripheral) - Collaborate with other specialists to develop treatment plans - Contribute to research and educate dental professionals about ameloblastoma - Monitor for recurrence through analysis of subsequent biopsies and imaging studies
Oncologists	- Help in diagnosing and staging the tumor - Collaborate on treatment planning, including surgery and potential chemotherapy - Participate in multidisciplinary teams for coordinated care - Oversee long-term follow-up to detect recurrence or complications - Engage in research and clinical trials to improve treatment options

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018

Discussion: Ameloblastomas are aggressive tumors known for their local invasion and high recurrence rates, necessitating precise histological diagnosis and effective surgical intervention.[21] Conservative treatments like marsupialization, enucleation, and curettage, while preserving bone integrity, have alarming recurrence rates of 55% to 90%.[22] Conversely, radical treatments can lead to significant cosmetic and functional complications, including the need for free flap reconstruction.[23] Effective management is critical; complete excision with wide margins of about 1 to 2 cm is essential to minimize recurrence risks. If left untreated, ameloblastomas can cause severe complications such as tooth displacement, root resorption, paresthesia, and substantial bone loss. This underscores the urgent need for prompt diagnosis and intervention to protect both function and aesthetics.[24] Recent trends show a shift toward conservative strategies that aim to reduce the negative impacts of radical surgery, such as chewing difficulties and facial deformities. Healthcare professionals must deepen their understanding of diverse treatment options to effectively customize management strategies that prioritize the unique needs of each patient. By embracing a more nuanced approach, clinicians can enhance patient outcomes and quality of life, ensuring that treatment decisions align closely with individual circumstances and preferences. **Table 2 summarizes the key findings and comparisons regarding the management of ameloblastoma.**[25-32]

Table 2: Comparative analysis of ameloblastoma management

Aspect	Conservative Treatment	Radical Treatment
Treatment approach	Enucleation, marsupialization, enucleation with curettage	Resection with a bone margin, en bloc resection, segmental resection
Recurrence rate	64.9%	12%
Risk factors for recurrence	Multilocular lesions, follicular histopathology	Lower risk associated with wide resection
Mean age of subjets	43.34 ± 8.5 years	Average age of recurrent cases: 36.18 ± 5.47 years
Lesion appearance	70% multilocular among recurrent cases	Unilocular lesions predominantly
Histopathological variants	Solid/multicystic (82% recurrence); follicular common	Similar predominance of solid/multicystic types
Follow-up period	Average of 6.2 years	Recurrences can occur 10-15 years post-treatment
Recommendations	Conservative for younger patients; higher recurrence risk	Radical surgery recommended for multicystic types
Study Comparisons	Support for high recurrence rates with conservative treatment	Evidence for lower recurrence rates with radical treatment

The analysis of recurrent ameloblastomas revealed several risk factors, including multilocular radiographic appearance, follicular histopathology, and conservative treatment. Among the cases examined, conservative management was associated with a significantly higher recurrence rate. While the majority of cases of about 62% were unilocular ameloblastomas, multilocular lesions exhibited a higher rate of recurrence.[33] **Table 3** provides an overview of the key authors

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018

and their contributions to the understanding of ameloblastoma management, particularly focusing on age, recurrence rates, and treatment recommendations.[34-46]

Table 3: Principal researchers and their ameloblastoma findings

Author	Study Result
Krishnapillai et al.	Reported mean age of 30 years; highest cases in the 3rd decade.
More et al.	Mean age reported as 43.5 years; similar findings regarding age demographics.
Hasegawa et al.	Mean age of 28.2 years; indicated variations in age incidence across regions.
Almeida et al.	Mean age of 38 years; supports the findings of the present study.
Arotiba et al.	Reported highest recurrence rates in the 3rd and 4th decades.
Milman et al.	Similar findings regarding age of recurrence
Fregnani et al.	Mandibular predominance noted; solid ameloblastomas more prevalent than unicystic.
Cadavid et al.	Reported higher incidence of multilocular ameloblastomas; mentions common plexiform and follicular variants.
Hendra et al.	Suggested follicular and multicystic types are associated with higher recurrence rates.
Laborde et al.	Conservative treatment associated with a recurrence rate of 90.9%.
Fregnani et al.	Ruptured basal cortical bone associated with a threefold increase in recurrence risk.
Antonoglou et al.	Found that radical surgery was associated with decreased recurrence over a 5-year follow-up.
Bansal et al.	Recommended conservative management for younger patients to minimize functional and aesthetic side effects.

According to the 2005 World Health Organization (WHO) histological classification of head and neck tumors, ameloblastoma can be classified into four subtypes: solid/multicystic (which includes follicular and plexiform variants), unicystic, extraosseous/peripheral, and desmoplastic.[47]

Solid / Multicystic ameloblastoma:

It account for approximately 1% of all jaw tumors and around 10% of odontogenic tumors.[48] These tumors are particularly aggressive, infiltrating surrounding tissues and significantly increasing the risk of recurrence post-surgery. Thus, prompt and precise diagnosis is crucial for effective management. [49] On a radiograph, a solid or multicystic ameloblastoma appears as a multilocular radiolucency with well-defined,

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018

scalloped margins. It can also appear as a soap bubble, honeycomb, or tennis racket pattern (**Figure 7**).[50]



Figure 7: Panaromphic radiograph depicting multilocular radiolucency of right angle of mandible
Courtesy: Menezes JDD, Yaedú RYF, Valente AC, Oliveira M, Taveira LAA, Rubira Bullen IRF. Recurrence of multicystic ameloblastoma: case report. RFO. 2023; 20(3):355-60.

The treatment approaches for ameloblastoma vary widely, from conservative methods like bone curettage to extensive segmental resection. Key techniques include marsupialisation (**Figure 8**), cryosurgery (**Figure 9**), electrocautery, sclerotherapy, and radiotherapy (**Figure 10**).[51]



Figure 8: Marsupilization
Courtesy: https://www.youtube.com/watch?app=desktop&v=uRtmX7naexQ



Figure 9: Cryosurgical treatment of ameloblastoma
Courtesy: Choy MG. Cryosurgical treatment of ameloblastoma: case report. Maxillofac Plast Reconstr Surg. 2012; 34:226-32.

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018



Figure 10: Radiotherapy of ameloblastoma
Courtesy: https://oraclehnc.org.uk/head-and-neck-cancer-types/mouth-cancer

This variant necessitate radical surgical excision, ensuring a 1-2 cm safety margin beyond the lesion.[52] Conservatively treated cases, such as those managed through enucleation and curettage, have recurrence rates ranging from 55% to 90%.[53] In contrast, radical resection achieves a much lower recurrence rate of only 5%.[54] Total resection remains the most effective treatment, yielding the lowest recurrence rates. However, the balance between the benefits of radical surgery and the potential for irreversible sequelae must be carefully considered.[55]Treatment protocols should be individualized based on lesion characteristics and patient circumstances, aiming for optimal outcomes with minimal trauma.[56] The histopathological variant influences these rates: follicular ameloblastoma has a recurrence rate of 29.5%, compared to 16.7% for plexiform and just 4.5% for acanthomatous variants (**Figure 11**) .[57]



Figure 11: Histopathological picture depicting solid/ multicystic ameloblastoma
Courtesy: Milman T, Ying GS, Pan W, LiVolsi VA. Ameloblastoma: 25 year experience at a single institution. Head Neck Pathol. 2016; 10(4):425-32.

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018

This pathological entity pose significant challenges, often leading to masticatory dysfunction, altered mandibular movements, and facial disfigurement.[58] Comprehensive treatment plans must prioritize rehabilitation to restore functional, anatomical, and aesthetic integrity, thereby enhancing the patient's quality of life. Surgical excision often requires adjacent jawbone resection, which can result in profound cosmetic deformity.[59] Microvascular surgery has emerged as the preferred method for reconstructing large mandibular defects, with donor sites including the fibula, iliac crest, radial forearm, and scapula. The fibula is particularly advantageous due to its length, thickness, and minimal donor site morbidity.[60] Post-surgical reconstruction is vital for restoring jaw integrity and function.[61] In cases where complete surgical removal is unachievable or when recurrence risk is elevated, radiation therapy may serve as an adjunct treatment.[62] Custom dental prosthetics crafted by prosthodontists or dentists play a crucial role in replacing missing teeth and restoring damaged oral structures.[63] A multidisciplinary team approach is essential for comprehensive patient care, addressing various needs such as nutritional guidance and rehabilitation. Accurate diagnosis through clinical and imaging examinations, including computed tomography and radiographs, underpins a well-informed treatment plan.[64]

Unicystic Ameloblastoma

It closely resembles dentigerous cysts in both clinical and radiological presentations, particularly when associated with retained teeth. This striking similarity often makes differentiation challenging, necessitating histopathological examination to identify a cystic cavity partially or completely lined by ameloblastic-type epithelium. Some cases may also reveal nodules within the cavity, further complicating diagnosis.[65] Once a unicystic ameloblastoma is suspected, determining its subtype is critical, as it can manifest as luminal, intraluminal, or mural (**Figure 12**).[66] Luminal lesions feature a fibrous tissue layer covered by ameloblastic epithelium, while intraluminal lesions exhibit plexiform characteristics with epithelial projections extending into the cavity.[67] Mural lesions, characterized by invasive fibrous tissue, require a more aggressive treatment approach due to their heightened risk of recurrence.[68] Radiographically, it present as single (**Figure 13**) or multiple radiolucent lesions with well-defined borders, occasionally displaying sclerotic margins.



Figure 12: Histopathological specimen showing unicystic type of ameloblastoma
Courtesy: Hertog D, Bloemena E, Aartman IHA, van der Waal I. Histopathology of ameloblastoma of the jaws: some critical observations based on a 40 years single institution experience. Med Oral Patol Oral Cir Bucal. 2011; 17(1):e76-82.



Figure 13: Panaromic radiograph depicting unilocular radiolucent lesion at right angle of mandible Courtesy: Wright JM, Soluk Tekkeşin M. Odontogenic tumors: where are we in 2017? J Istanbul Univ Fac Dent. 2017; 51(3 Suppl 1):S10-S30.

A thorough clinical and imaging evaluation is essential for tailoring the most effective treatment strategy.[69] Unilocular cases are generally less aggressive, offering opportunities for less invasive surgical interventions like enucleation and curettage. In contrast, multilocular ameloblastomas demand more aggressive management, including resection with safety margins and potential reconstruction of bone segments.[70] Unicystic ameloblastoma, generally considered less aggressive than solid or multicystic variants, is often managed through enucleation and peripheral ostectomy, sometimes supplemented by physicochemical treatments like cryotherapy or electrocautery.[71] To further reduce recurrence risks, surgeons can combine traditional surgical techniques with ancillary methods such as Carnoy's solution, cryotherapy, or diathermy. The Brosch procedure is a surgical technique used in the management of ameloblastoma, particularly for cases where the tumor is located in the mandible. It involves resection of the affected bone along with a margin of healthy tissue to ensure complete removal of the tumor. This approach helps to minimize the risk of recurrence, which is a common concern with ameloblastomas due to their infiltrative nature. This procedure may be combined with reconstruction techniques to restore the functionality and aesthetics of the affected area. It's important for the surgical plan to be tailored to the individual case, considering factors like the size and location of the tumor, as well as the patient's overall health. Overall, the Brosch procedure is one of several options available for effectively managing ameloblastoma, aiming for a balance between complete excision and functional preservation. applies to which variant of ameloblastoma This particularly applicable to unicystic ameloblastoma and solid/multicystic ameloblastoma variants. These types often exhibit infiltrative behavior, necessitating a comprehensive surgical approach to ensure complete removal and minimize the risk of recurrence. In cases of unicystic ameloblastoma, the Brosch procedure allows for resection of the cystic lesion along with surrounding healthy tissue. These multifaceted approaches underscore the necessity of personalized treatment plans that effectively balance efficacy with patient safety and recovery. However, certain cases may still necessitate more aggressive surgical resection. This tailored approach ensures that each patient receives the most appropriate care, optimizing outcomes while minimizing complications.[72]

Peripheral Amelolastoma:

The initial well-documented case of peripheral ameloblastoma was described by Stanley and Krogh in 1959, with very few cases reported since then.[73] This condition primarily affects men, with approximately 65% of cases involving males and a male-to-female ratio of 1.9:1. The average age at diagnosis is 52.1 years, but cases can range from 9 to 92 years. Peripheral ameloblastomas typically occur in mandible, especially in the premolar region, followed by the lower anterior (**Figure 14**) and maxillary tuberosity areas. This wide age range underscores the need for heightened awareness and prompt diagnosis across all demographics. They have male predilictiom, affecting approximately 65% of cases.[74] It typically present as slow-growing, painless, exophytic lesions in the gingiva or oral mucosa, varying in color from pink to dark red. They are generally firm, sessile masses with a smooth surface and may occasionally exhibit a papillary or warty appearance. Bleeding is rare.[75] These tumors are most commonly located in the anterior gingiva and occur more frequently in the mandible, accounting for 70.9% of cases, compared to 29.1% in the

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018

maxilla.[76] Potential sources of this variant include remnants of odontogenic tissue from the vestibular lamina, pluripotent cells in the basal cell layer of the mucosal epithelium, and cells from minor salivary glands, indicating that these lesions are true neoplasms rather than embryological hamartomas. While peripheral ameloblastomas can display histologic features similar to intra-osseous infiltrating ameloblastoma, cases with low-grade malignant characteristics are exceedingly rare (**Figure 15**).[77]



Figure 14: Intra oral picture of peripheral ameloblastoma on maxillary labial gingival in between right canine and first premolar
Courtesy: Shetty K. Peripheral ameloblastoma: An etiology from surface epithelium? Case report and review of literature. Oral Oncol Extra. 2005; 41(9):211-5.



Figure 15: Histopathological specimen of unicystic ameloblastoma
Courtesy: Vezhavendhan N, Vidyalakshmi S, Muthukumaran R, Santhadevy A, Sivaramakrishnan M, Gayathri C. Peripheral ameloblastoma of the gingiva. Autops Case Rep. 2019 Dec 13; 10(1):e2019127.

Malignant peripheral ameloblastoma has also been documented, but this subtype represents only 1 to 5 percent of all ameloblastomas and typically exhibits more benign behavior, with minimal bony involvement that allows for conservative treatment.[78] Although the deep margin

does not usually invade bone extensively, it may appear scalloped on radiographic images.[79] Advanced imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) can accurately delineate these lesions.[80] Despite their characteristic appearances, a formal diagnosis requires histological examination to exclude other peripheral odontogenic tumors. It demonstrate benign behavior, with an average growth rate lower than that of other ameloblastoma subtypes, measuring 0.17 cm^3 per month compared to 0.81 cm^3 per month for more aggressive types.[81] Additionally, bone involvement is typically minimal, often appearing as a slight depression on the bone surface, referred to as "cupping" or "saucerization."[82] The preferred surgical approach for peripheral ameloblastoma is conservative local excision, without the need to remove bone or teeth.[83] The treatment strategy for peripheral ameloblastoma is typically conservative due to its benign nature. Surgical excision is the primary method, aiming for complete removal with adequate margins to reduce recurrence risk. Smaller lesions may be treated with local excision, while larger tumors might require more extensive surgery.[84] Regular follow-up is essential to detect any signs of recurrence. If the tumor shows malignant features, a more aggressive approach may be necessary, including wider resection and adjunctive therapies. Overall, these rare tumors require careful management, accurate diagnosis, and thorough follow-up for optimal outcomes.[85]

Desmoplastic Ameloblastoma

Desmoplastic ameloblastoma is characterized by a collagen-rich stroma interspersed with ovoid epithelial tumor cell islets (**Figure 16**).[86] It typically occurs in the maxillary anterior region and can mimic benign fibro-osseous lesions on radiographic exams, complicating treatment planning.[87] Constituting 0.9% to 12.1% of all ameloblastomas, this type has a mean presentation age of 42.3 years, with a slight predilection for Asian populations.[88] Originating from the periodontal membrane or epithelial rests of Malassez, desmoplastic ameloblastoma often presents as a slow-growing, painless lesion.[89]



Figure 16: Histopathological feature of desmoplastic ameloblastoma
Courtesy: Hertog D, Bloemena E, Aartman IHA, van der Waal I. Histopathology of ameloblastoma of the jaws; some critical observations based on a 40 years single institution experience. Medicina Oral Patol Oral Cir Bucal. 2011; 17(1):e76-82.

Approximately half of these tumors are located in the maxilla, particularly in the anterior or premolar areas. Unlike unicystic or classic types, which are typically found in the posterior mandible, desmoplastic variants may exhibit more aggressive behavior due to their potential for larger size and early invasion of adjacent structures. Radiographically, desmoplastic ameloblastoma appears as a mixed radiolucent and radiopaque lesion, often with poorly defined borders that suggest an infiltrative process (**Figure 17**).[90]

International Journal Dental and Medical Sciences Research
Volume 6, Issue 6, Nov - Dec 2024 pp 50-67 www.ijdmsrjournal.com ISSN: 2582-6018



Figure 17: Desmoplastic ameloblastoma: mixed radiolucent and radiopaque characteristics Courtesy: Shetty K. Peripheral ameloblastoma: An etiology from surface epithelium? Case report and review of literature. Oral Oncol Extra. 2005; 41(9):211-5.

A definitive diagnosis is made through histopathological examination, which reveals stromal desmoplasia, epithelial islands, and peripheral cuboidal cells. It can be misdiagnosed as other odontogenic tumors due to variable histological features.[91] Treatment primarily involve surgical resection, as enucleation or curettage may lead to recurrence. The recurrence rate for desmoplastic ameloblastoma is higher than for other types of ameloblastoma. Thus, complete resection is emphasized to minimize the risk of recurrence. Due to its unique clinical and histological characteristics, desmoplastic ameloblastoma should be included in differential diagnoses for lesions in the anterior maxilla or mandible. Further study and long-term follow-up are necessary to enhance understanding of its behavior and prognosis.[92]

Future Prospects in the Management of Ameloblastoma: The management of ameloblastoma is evolving, with several promising avenues aimed at improving patient outcomes, reducing recurrence rates, and enhancing the overall treatment experience. Here are key future prospects in the management of this tumor:

1. **Minimally invasive techniques**: Advances in surgical techniques, such as endoscopic and robotic-assisted surgeries, may allow for more precise resections with less morbidity. These approaches could enhance recovery times and reduce complications.
2. **Targeted therapies:** Research into the molecular and genetic underpinnings of ameloblastoma could lead to the development of targeted therapies. Identifying specific genetic mutations and signaling pathways involved in tumorigenesis may open avenues for novel pharmacological treatments.
3. **Enhanced imaging modalities:** Improved imaging technologies, including 3D imaging and advanced MRI techniques, could provide better preoperative assessments, allowing for more accurate planning and monitoring of tumor extent and recurrence.
4. **Biomarker Development:** Identifying biomarkers for ameloblastoma could facilitate early diagnosis and help predict tumor behavior, guiding treatment decisions and monitoring for recurrence.
5. **Personalized treatment plans:** Advances in genomics and personalized medicine may enable tailored treatment approaches based on individual patient profiles, optimizing both surgical and adjunct therapies.
6. **Regenerative Techniques:** Innovations in tissue engineering and regenerative medicine could improve reconstructive outcomes post-resection, with potential for utilizing stem cells or bioengineered materials to restore form and function.

7. **Longitudinal studies and databases:** Establishing comprehensive databases and conducting long-term studies can enhance understanding of the long-term outcomes and recurrence rates associated with various management strategies, informing best practices.
8. **Multidisciplinary approaches:** A collaborative approach involving surgeons, oncologists, pathologists, and radiologists can enhance the management of ameloblastoma, ensuring a holistic treatment plan that addresses all aspects of care.
9. **Patient-centric care models:** Increasing focus on patient education, support, and shared decision-making can improve the patient experience and adherence to treatment plans, leading to better outcomes.
10. **Innovative follow-up protocols:** Developing standardized follow-up protocols using modern surveillance methods could enhance early detection of recurrences, allowing for timely intervention.

As research progresses and new technologies emerge, the future management of ameloblastoma holds the potential for more effective, less invasive, and personalized treatment strategies that significantly improve patient outcomes.[93]

II. CONCLUSION:

Treatment for ameloblastoma is comprehensive and often involves a combination of surgery, reconstruction, and supportive therapies. A tailored approach that addresses both the tumor and its impact on the patient's quality of life is essential for optimal outcomes. Regular follow-up is crucial to monitor for any signs of recurrence and to ensure the best possible recovery. Treatment of a patient with an ameloblastoma should be based on accurate clinical details, radiographs, special imaging, and a representative biopsy, followed and reviewed by an oral pathologist and a maxillofacial surgeon.

Financial support and sponsorship Nil
Conflicts of interest There are no conflicts of interest

REFERENCES

[1]. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol. 2007; 30(6):645–8.
[2]. Zhang X, et al. Ameloblastoma: An analysis of 162 cases. J Oral Maxillofac Surg. 2016; 74(2):222-31.
[3]. Johnson NR, Gannon OM, Savage NW, Batstone MD. Frequency of odontogenic cysts and tumors: a systematic review. J Investig Clin Dent. 2014; 5(1):9–14.
[4]. Oomens MA, van der Waal I. Epidemiology of ameloblastomas of the jaws; a report from the Netherlands. Med Oral Patol Oral Cir Bucal. 2014; 19(6):e581–3.
[5]. Gerzenshtein J, Zhang F, Caplan J, Anand V, Lineaweaver W. Immediate mandibular reconstruction with microsurgical fibula flap transfer following wide resection for ameloblastoma. J Craniofac Surg. 2006; 17(1):178–82.
[6]. Adekeye EO, Lavery KM. Recurrent ameloblastoma of the maxillo-facial region: clinical features and treatment. J Maxillofac Surg. 1986; 14(3):153–7.
[7]. Shahbazian M, Kalantari R, et al. Ameloblastoma: Review of literature and its management. J Oral Maxillofac Surg. 2015; 73 (12):2337-44.
[8]. Underhill TE, Katz JO, Pope TL, Dunlap CL. Radiologic findings of diseases involving the maxilla and mandible. AJR Am J Roentgenol. 1992; 159(2):345–50.
[9]. Yadav A, Nirmal R, et al. Ameloblastoma: A review of surgical management. J Maxillofac Oral Surg. 2014; 13(3):393-7.
[10]. Eversole LR, Leider AS, Hansen LS. Ameloblastomas with pronounced desmoplasia. J Oral Maxillofac Surg. 1984; 42(11):735–40.
[11]. Aisenberg MS. Histopathology of ameloblastomas. Oral Surg Oral Med Oral Pathol. 1953; 6(9):1111–28.
[12]. McClary AC, West RB, McClary AC, et al. Ameloblastoma: a clinical review and trends in management. Eur Arch Otorhinolaryngol. 2016; 273(7):1649–61.
[13]. Zhang J, Gu Z, Jiang L, Zhao J, Tian M, Zhou J, Duan Y. Ameloblastoma in children and adolescents. Br J Oral Maxillofac Surg. 2010; 48(7):549–54.
[14]. Alobid I, et al. The role of surgery in the management of ameloblastoma: A review. Curr Oncol Rep. 2016; 18(4):25.
[15]. Terada T, et al. Case report of ameloblastoma: Review of treatment outcomes. J Oral Maxillofac Surg. 2012; 70(3):e246-50.
[16]. Soltani M, et al. Histopathological features of ameloblastoma: A comprehensive study. J Oral Pathol Med. 2018; 47(7):650-6.
[17]. Benlyazid A, Lacroix-Triki M, Aziza R, Gomez-Brouchet A, Guichard M, Sarini J. Ameloblastic carcinoma of the maxilla: case report and review of the literature.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104 (6):e17-24.
[18]. Tamme T, Tiigimäe J, Leibur E. Mandibular ameloblastoma: a 28-year retrospective study of the surgical treatment results. Minerva Stomatol. 2010; 59(11-12):637–43.
[19]. Gardner DG, Corio RL. Plexiform unicystic ameloblastoma: a variant of ameloblastoma with a low-recurrence rate after enucleation. Cancer. 1984; 53(8):1730–5.
[20]. Chae MP, Smoll NR, Hunter-Smith DJ, Rozen WM. Establishing the natural history and growth rate of ameloblastoma with implications for management: systematic review and meta-analysis. PLoS One. 2015; 10(2):e0117241.
[21]. Li TJ, Wu YT, Yu SF, Yu GY. Unicystic ameloblastoma: a clinicopathologic study of 33 Chinese patients. Am J Surg Pathol. 2000; 24(10):1385–92.
[22]. Antonoglou GN, Sándor GK. Recurrence rates of intraosseous ameloblastomas of the jaws: a systematic review of conservative versus aggressive treatment approaches and meta-analysis of non-randomized studies. J Craniomaxillofac Surg. 2015; 43(1):149–57.
[23]. Urken ML, Buchbinder D, Costantino PD, Sinha U, Okay D, Lawson W, Biller HF. Oromandibular reconstruction using microvascular composite flaps: report of 210 cases. Arch Otolaryngol Head Neck Surg. 1998; 124(1):46–55.
[24]. Chang W, et al. Ameloblastoma: A case report and literature review. J Craniofac Surg. 2016; 27(3):801-5.
[25]. Schulten EAJM, et al. Ameloblastoma in children: A systematic review. Int J Oral Maxillofac Surg. 2021; 50(1):49-56.
[26]. Naiem M, et al. The association of ameloblastoma with other odontogenic lesions: A review of the literature. J Oral Pathol Med. 2018; 47(6):585-590.
[27]. Khosravi M, et al. Ameloblastoma: A systematic review of clinical, radiological and histopathological findings. Oral Dis. 2018; 24 (5):868-78.
[28]. Batstone MD, et al. The management of ameloblastoma: A review. J Oral Maxillofac Surg. 2012; 70(7):1523-34.
[29]. Garret A, et al. Ameloblastoma: Review and clinical experience. Dent Update. 2017; 44 (1):20-22.
[30]. Rogers SN, et al. Quality of life in patients with ameloblastoma: A retrospective study. Int J Oral Maxillofac Surg. 2013; 42(10):1185-90.
[31]. Cruz E, et al. Ameloblastoma: Clinical and therapeutic implications. Acta Odontol Scand. 2017; 75(3):189-95.
[32]. Palacios-González B, et al. Radiographic characteristics of ameloblastoma: A literature review. Radiol Oncol. 2018; 52(1):1-8.
[33]. Krishnapillai R, Angadi PV. A clinical, radiographic, and histologic review of 73 cases of ameloblastoma in an Indian population. Quintessence Int. 2010; 41(5):e90–e100.
[34]. More C, Tailor M, Patel HJ, Asrani M, Thakkar K, Adalja C. Radiographic analysis of ameloblastoma: A retrospective study. Indian J Dent Res. 2012; 23(5):698.
[35]. Hasegawa T, Imai Y, Takeda D, Yasuoka D, Ri S, Shigeta T, Minamikawa T, Shibuya Y, Komori T. Retrospective study of ameloblastoma: the possibility of conservative treatment. Kobe J Med Sci. 2013; 59 (4):e112–121.
[36]. Almeida Rde A, Andrade ES, Barbalho JC, Vajgel A, Vasconcelos BC. Recurrence rate following treatment for primary multicystic ameloblastoma: systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2016; 45(3):359–367.
[37]. Arotiba GT, Effiom AO, Ayodele AS, Ogundana MO, Gbotolorun MO, Olasoji HO, et al. A classification system for recurrent ameloblastoma of the jaws-review of 30 cases in Nigerians. Nig Q J Hosp Med. 2012; 22(1):44–51.
[38]. Milman T, Lee V, LiVolsi V. Maxillary ameloblastoma with orbital involvement: an institutional experience and literature review. Ophthalmic Plast Reconstr Surg. 2016; 32(6):441–446.
[39]. Fregnani ER, da Cruz Perez DE, de Almeida OP, Kowalski LP, Soares FA, de Abreu Alves F. Clinicopathological study and treatment outcomes of 121 cases of ameloblastomas. Int J Oral Maxillofac Surg. 2010; 39(2):145–149.
[40]. Cadavid AMH, Araujo JP, Coutinho-Camillo CM, Bologna S, Celso Augusto Lemos CA, Lourenço SV. Ameloblastomas: current aspects of the

new WHO classification in an analysis of 136 cases. Surg Exp Pathol. 2019; 2:17.
[41]. Chrcanovic BR, et al. Ameloblastoma: A systematic review of clinical and epidemiological features. Oral Dis. 2014; 20(2):110-6.
[42]. Hendra FN, Natsir Kalla DS, Van Cann EM, de Vet HCW, Helder MN, Forouzanfar T. Radical vs conservative treatment of intraosseous ameloblastoma: Systematic review and meta-analysis. Oral Dis. 2019; 25(7):1683–1696.
[43]. Laborde A, Nicot R, Wojcik T, Ferri J, Raoul G. Ameloblastoma of the jaws: Management and recurrence rate. Eur Ann Otorhinolaryngol Head Neck Dis. 2017; 134 (1):7–11
[44]. Antonoglou GN, Sándor GK. Recurrence rates of intraosseous ameloblastomas of the jaws: a systematic review of conservative versus aggressive treatment approaches and meta-analysis of non-randomized studies. J Craniomaxillofac Surg. 2015; 43(1):149–157.
[45]. Bansal S, Desai RS, Shirsat P, Prasad P, Karjodkar F, Andrade N. The occurrence and pattern of ameloblastoma in children and adolescents: an Indian institutional study of 41 years and review of the literature. Int J Oral Maxillofac Surg. 2015; 44(6):725–731.
[46]. Kauffman J, Scholl SM. Ameloblastoma: a literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 94(4):458-66.
[47]. Sándor GK, Antonoglou GN. Management of ameloblastoma: current trends. J Oral Maxillofac Surg. 2015; 73(3):593-606.
[48]. Vandenberghe M, Van den Berghe L, De Bruyn H. The role of imaging in the diagnosis and management of ameloblastoma. Br J Oral Maxillofac Surg. 2006; 44(5):388-93.
[49]. Kamath AT, Muliya V, Ganesh K. Ameloblastoma in a child: a case report. J Clin Pediatr Dent. 2014; 38(4):355-8.
[50]. Suri S, Dhingra C, Sood N, Yadav A. Unicystic ameloblastoma: a review. J Clin Diagn Res. 2014; 8(4):ZC18-ZC20.
[51]. Al-Khateeb T, et al. Ameloblastoma: A review of clinical and histopathological features. J Oral Pathol Med. 2013; 42(8):585-9.
[52]. Gupta S, Kumar A, Singh M, Shukla M. Radiological and histopathological review of ameloblastoma: a case report. Indian J Radiol Imaging. 2016; 26 (2):223-7.
[53]. Ali A, Sadiq M, et al. Ameloblastoma: A clinicopathological study. Ann Maxillofac Surg. 2017; 7(2):180-6.
[54]. Teymoortash A, Riedel F, Riedel K, et al. Recurrence rate of ameloblastoma: A retrospective study of 100 patients. Oral Oncol. 2014; 50(5):459-63.
[55]. Li TJ, Yu GY, Yu SF, et al. Clinical features and treatment outcomes of ameloblastomas: a retrospective study of 70 cases. J Oral Maxillofac Surg. 2008; 66(8):1533-41.
[56]. Arora S, Malhotra M, Sharma P. Ameloblastoma in children: a clinical review. J Indian Soc Pedod Prev Dent. 2011; 29(3):236-9.
[57]. Eversole LR, K. Ameloblastoma: a clinical and radiographic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 86(2):245-50.
[58]. Wei X, Yu GY, Li TJ, et al. Recurrence and treatment strategies for ameloblastoma: A meta-analysis. Oral Oncol. 2014; 50 (6):599-605.
[59]. Wadhawan R, Vellachalil F, Thavalam Parambil A, Sailendran S, EP Thanuja, Bhartia A. Revolutionizing jaw reconstruction: a comprehensive review of free fibula grafts in maxillofacial surgery. International Journal of Dental and Medical Sciences Research. 2024; 6(4):365-74.
[60]. Lavery KM, Adekeye EO. Ameloblastoma: a review of clinical and radiological features. Int J Oral Maxillofac Surg. 1991; 20 (1):36-9.
[61]. Kharbanda OP, Shankaranarayanan V. Ameloblastoma: A literature review. Contemp Clin Dent. 2011; 2(2):94-7.
[62]. Cummings C, Marentette L. Management of ameloblastoma: The role of surgery and adjunctive therapy. J Craniofac Surg. 2004; 15(2):263-6.
[63]. Tysome JR, Rauff Z, et al. Ameloblastoma: A challenging entity. Eur J Surg Oncol. 2012; 38(11):1045-51.
[64]. D'Souza A, Asha N, Ramesh R. Ameloblastoma in children: Case series and review. Pediatr Dent J. 2015; 25(1):16-22.
[65]. Maffei J, Freitas J, et al. Histological subtypes of ameloblastoma: A clinicopathological study. Int J Oral Maxillofac Surg. 2013; 42(8):971-8.

[66]. Shear M, Speight P. Ameloblastoma: A review of the literature. Oral Dis. 2007; 13(2):145-50.
[67]. Jadhav R, Bhalerao S, Patil P. Ameloblastoma: A review. J Oral Maxillofac Pathol. 2011; 15(1):30-3.
[68]. Puri S, Mehndiratta M, Bhattacharyya I. Ameloblastoma: A review of its pathogenesis. Indian J Dent Res. 2011; 22(5):653.
[69]. Khamis M, Razaq N, et al. Management of ameloblastoma: the role of surgical intervention. Saudi Med J. 2013; 34(6):637-42.
[70]. Takeda Y, Saito C, et al. The surgical treatment of ameloblastoma: A review of the literature. Oral Maxillofac Surg. 2015; 19(2):97-102.
[71]. Hasegawa T, Imai Y, et al. Conservative treatment of ameloblastoma: A review of clinical evidence. Kobe J Med Sci. 2013; 59(1):e48-53.
[72]. Dhananjay R, Choudhary D. Ameloblastoma: Review of current concepts. J Nat Sci Biol Med. 2014; 5(2):321-4.
[73]. Laskin DM. Ameloblastoma: Current concepts in treatment. Oral Maxillofac Surg Clin North Am. 2014; 26(4):431-41.
[74]. Kim H, Kim S, et al. Ameloblastoma: A 20-year retrospective study. Head Neck. 2014; 36(3):457-65.
[75]. Reddy V, Rajan S, et al. Review of ameloblastoma: A challenging entity. J Indian Acad Oral Med Radiol. 2015; 27(1):41-6.
[76]. Santosh AB, Mohan R, et al. Treatment of ameloblastoma: An overview. Oral Maxillofac Surg. 2017; 21(1):1-9.
[77]. Gunturi S, Bhattacharyya R, et al. A retrospective study of ameloblastoma: Clinical and radiological findings. J Maxillofac Oral Surg. 2017; 16(1):12-8.
[78]. Nascimento D, Souza A, et al. Conservative treatment for ameloblastoma: A systematic review. Int J Oral Maxillofac Surg. 2015; 44(2):228-35.
[79]. Bansal A, Gupta R, Bansal R, et al. Ameloblastoma: A comprehensive review of its diagnosis and management. J Clin Diagn Res. 2015; 9(7):ZE05-ZE08.
[80]. Gupta N, et al. Ameloblastoma: A clinical, radiological, and histological review. Dent Res J (Isfahan). 2012; 9(6):692-701.
[81]. Jiang J, et al. The molecular pathogenesis of ameloblastoma: Current perspectives. Oral Oncol. 2018; 78:67-73.
[82]. Mishra S, Tiwari A, et al. Ameloblastoma in a young adult: A rare case report with review of literature. J Clin Diagn Res. 2018; 12(5):ZD15-ZD17.
[83]. Satyam K, Sinha A, et al. Role of imaging in the diagnosis of ameloblastoma: A review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 122(1):1-7.
[84]. Sarode SC, Sarode GS, et al. Ameloblastoma: A review of molecular alterations and their implications for treatment. J Oral Pathol Med. 2019; 48(3):185-192.
[85]. Siddiqui S, et al. Clinical presentation and management of ameloblastoma: A retrospective analysis. Ann Maxillofac Surg. 2020; 10(1):75-80.
[86]. Wang X, et al. The role of bone regeneration in ameloblastoma: A systematic review. Int J Oral Maxillofac Surg. 2020; 49(1):45-54.
[87]. Zhou J, et al. Immunohistochemical expression of p53 in ameloblastoma: A potential marker for recurrence. J Oral Pathol Med. 2014; 43(6):409-414.
[88]. Yoshida R, et al. Ameloblastoma: Current surgical approaches and challenges. *Head Neck. 2016; 38(8):1196-1204.
[89]. Patel S, et al. Ameloblastoma: An evaluation of recurrence rates and management strategies. Br J Oral Maxillofac Surg. 2015; 53(5):445-452.
[90]. Calhoun C, et al. Clinicopathological features of ameloblastoma: A review of 100 cases. J Oral Maxillofac Surg. 2019; 77(12):2414-2421.
[91]. Van der Waal I, et al. Long-term follow-up of patients treated for ameloblastoma. Int J Oral Maxillofac Surg. 2014; 43(6):677-682.
[92]. Tsai CC, et al. The impact of surgical margins on recurrence rates in ameloblastoma: A meta-analysis. J Craniofac Surg. 2017; 28(4):1043-1048.